Preparation and in vitro characterization of monoclonal antibody ranibizumab conjugated magnetic nanoparticles for ocular drug delivery

Abstract

Gold coated magnetite nanoparticles were prepared and coated with ranibizumab as an ocular drug delivery system. The surface morphologies of the nanoparticles were determined by Scanning Electron Microscopy (SEM). The size and surface charge were determined by using the dynamic light scattering (DLS) technique. Crystallographic properties of the gold coated Fe 3 O 4 nanoparticles were recorded on X-ray diffractometer (XRD) the XRD pattern of nanoparticlees were shown to have uniqe Fe 3 O 4 and gold peaks. Conjugation of ranibizumab onto nanoparticles was achieved using the physical adsorption method. The amount of ranibizumab on the surface of the nanoparticles was determined by thermogravimetric analysis (TGA). In the in vitro release studies performed using UV spectroscopy; it was found that almost 60% of antibodies were released within the first 30 minutes. Antibody activity after release studies was also proved with ELISA. Non-toxicity of gold coated Fe 3 O 4 particles were proved with MTT. Results of the studies, showed that the antibody conjugated magnetic nanoparticle system could be a potential treatment system for ocular diseases.

Lipid-Based Nanocarriers as Topical Drug Delivery Systems for Intraocular Diseases

“…Even though gold nanoparticles have presented an easy production and a biocompatible profile [ 69 , 70 , 71 ], their accumulation in dendritic cells, as well as in macrophages, stem cells or endothelial cells, have shown to alter their cytokine secretion, where this accumulation induces oxidative stress, leading to cytotoxicity [ 72 , 73 , 74 ]. Several studies have shown the utility and promising carriage of different drugs into gold nanoparticles to increase penetration and bioavailability to deeper ocular tissues [ 68 , 75 , 76 ]. Cho et al evaluated in vivo mice the use of these nanoparticles in corneal neovascularization and obtained a significant reduction (39.8%) of it.…”

Recent achievements in nano-based technologies for ocular disease diagnosis and treatment, review and update

“…Nontoxicity of gold-coated Fe3O4 particles was shown with MTT. The results revealed that the antibody-conjugated MNPs can be a possible treatment system for eye disorders [ 99 ].…”

Nanotechnology for Age-Related Macular Degeneration

“…A novel nano-delivery system loaded with therapeutic proteins such as ranibizumab can be continuously delivered in vivo. In addition, this new delivery system can avoid the huge risks and costs of frequent intravenous injections [9][10][11][12].…”